Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells (Q40571427)

From Wikidata

Jump to navigation Jump to search

scientific article published on 31 March 2004

Language	Label	Description	Also known as
English	Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells	scientific article published on 31 March 2004

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

1 reference

based on heuristic

inferred from title

8

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Martin S. Tallman

9

object named as

Martin S Tallman

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Eleanor N. Fish

10

object named as

Eleanor N Fish

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

author name string

Simrit Parmar

1

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Efstratios Katsoulidis

2

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Amit Verma

3

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Yongzhong Li

4

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Antonella Sassano

5

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Lakhvir Lal

6

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Beata Majchrzak

7

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Leonidas C Platanias

11

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

language of work or name

0 references

publication date

31 March 2004

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

number of pages

8

1 reference

based on heuristic

inferred from page(s)

Journal of Biological Chemistry

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

279

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

24

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

25345-25352

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

STI571: a paradigm of new agents for cancer therapeutics

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Specific targeted therapy of chronic myelogenous leukemia with imatinib

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Structural organization of the bcr gene and its role in the Ph' translocation

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Role of the adapter protein CRKL in signal transduction of normal hematopoietic and BCR/ABL-transformed cells

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Structural basis for the autoinhibition of c-Abl tyrosine kinase

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Engagement of the CrkL adaptor in interferon alpha signalling in BCR-ABL-expressing cells

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Signaling via the interferon-alpha receptor in chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Interferon-alpha therapy for chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Cell context-specific effects of the BCR-ABL oncogene monitored in hematopoietic progenitors

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Activation of the p38 mitogen-activated protein kinase by type I interferons

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Role of p38alpha Map kinase in Type I interferon signaling

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Interferon-α Engages the Insulin Receptor Substrate-1 to Associate with the Phosphatidylinositol 3′-Kinase

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

The type I interferon receptor mediates tyrosine phosphorylation of the CrkL adaptor protein

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to all-trans-retinoic acid

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Activation of the p38 mitogen-activated protein kinase mediates the suppressive effects of type I interferons and transforming growth factor-beta on normal hematopoiesis

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Correlation between cytogenetic and molecular findings in human chronic myelogenous leukemia lines EM-2 and EM-3.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Mitogen- and stress-activated protein kinase-1 (MSK1) is directly activated by MAPK and SAPK2/p38, and may mediate activation of CREB

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

The nucleosomal response associated with immediate-early gene induction is mediated via alternative MAP kinase cascades: MSK1 as a potential histone H3/HMG-14 kinase

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

MSK2 and MSK1 mediate the mitogen- and stress-induced phosphorylation of histone H3 and HMG-14

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

MAP kinase-mediated signalling to nucleosomes and immediate-early gene induction

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Independent dynamic regulation of histone phosphorylation and acetylation during immediate-early gene induction

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Effects of combinations of therapeutic agents on the proliferation of progenitor cells in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Effects of the Tyrosine Kinase Inhibitor Imatinib Mesylate on a Bcr-Abl-Positive Cell Line: Suppression of Autonomous Cell Growth but No Effect on Decreased Adhesive Property and Morphological Changes

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

BCR-ABL binds to IRS-1 and IRS-1 phosphorylation is inhibited by imatinib in K562 cells

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Involvement of Akt kinase in the action of STI571 on chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Structural basis of inhibitor selectivity in MAP kinases

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

The p38 mitogen-activated protein kinase pathway and its role in interferon signaling

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Mitogen-activated protein kinase pathways

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Mitogen-activated protein kinases: specific messages from ubiquitous messengers

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

MAP kinases in the immune response

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Signal transduction by MAP kinases in T lymphocytes

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Map kinase signaling pathways and hematologic malignancies

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Chronic myelogenous leukemia: biology and therapy

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Resistance of Philadelphia-chromosome positive leukemia towards the kinase inhibitor imatinib (STI571, Glivec): a targeted oncoprotein strikes back

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571.

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Cytokines and anti-cytokine biologicals in autoimmunity: present and future

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Inhibitors of p38 mitogen-activated protein kinase: potential as anti-inflammatory agents in asthma?

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M400590200

21 January 2018

Identifiers

10.1074/JBC.M400590200

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

21 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40571427&oldid=1900646487"